|
|
4527 ROHTO PHARMACEUTICAL CO.,LTD.
|
|
06/30/2025 18:00 |
Corporate Governance Report |
06/03/2025 08:00 |
NOTICE OF CONVOCATION THE 89TH ORDINARY GENERAL MEETING OF SHAREHOLDERS |
05/19/2025 17:30 |
Notice of Dividend of Surplus |
05/13/2025 15:30 |
ROHTO Pharmaceutical Co., Ltd. Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 Reference |
05/13/2025 15:30 |
Financial Results Briefing for the Fiscal Year Ending March 31, 2025 |
05/13/2025 15:30 |
Medium- to Long- Term Growth Strategy 2025-2035 |
05/13/2025 15:30 |
Rohto Group Medium- to Long-Term Growth Strategy 2025-2035 |
05/13/2025 15:30 |
Consolidated Financial Results for the Year Ended March 31, 2025 |
05/09/2025 12:30 |
Notice on Changes of President and Chief Operating Officer and Other Officers |
04/25/2025 15:00 |
Announcement of the Initiation of Domestic Phase II Clinical Trial for Heart Failure Treatment "ADR-002K" |
04/21/2025 16:35 |
[Delayed]Announcement of Initiation of Phase II Clinical Trial in Japan for Ophthalmic Agent "ROH-001" |
02/27/2025 10:30 |
Notice Regarding Result and Completion of Repurchase of Shares through an Off-Auction Own Share Repurchase Transaction (ToSTNeT-3) |
02/26/2025 22:35 |
Notice on Determination of Terms of Issue of Zero Coupon Convertible Bonds due 2032 |
02/26/2025 17:10 |
Notice Regarding Repurchase of Shares through an Off-Auction Share Repurchase Transaction (ToSTNeT-3) |
02/26/2025 17:10 |
Notice Regarding Repurchase of Shares |
02/26/2025 17:10 |
Notice Regarding Issuance of Zero Coupon Convertible Bonds due 2032 |
02/12/2025 15:30 |
Notice of Revision of Dividend Forecast (Dividend Increase) |
02/12/2025 15:30 |
Financial Results Briefing for Q3 (Apr_Dec) of the Fiscal Year Ending March 31, 2025 |
02/12/2025 15:30 |
Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2025 |
11/13/2024 15:30 |
Financial Results Briefing for the First Half of the Fiscal Year Ending March 31, 2025 |
11/13/2024 15:30 |
Summary of Financial Results for the second quarter 2025 |
08/07/2024 15:00 |
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2025 (Three Months Ended June 30, 2024) |
08/07/2024 15:00 |
Consolidated Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2025 (Three Months Ended June 30, 2024) |
08/07/2024 15:00 |
Notice of Revision of Earnings Forecast and Dividend Forecast (Dividend Increase) |
|